Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.

Autor: Furman C; H3 Biomedicine Inc., Cambridge, Massachusetts., Puyang X; H3 Biomedicine Inc., Cambridge, Massachusetts., Zhang Z; H3 Biomedicine Inc., Cambridge, Massachusetts., Wu ZJ; H3 Biomedicine Inc., Cambridge, Massachusetts., Banka D; H3 Biomedicine Inc., Cambridge, Massachusetts., Aithal KB; Aurigene Discovery Technologies Ltd, Bangalore, Karnataka, India., Albacker LA; Foundation Medicine Inc., Cambridge, Massachuetts., Hao MH; H3 Biomedicine Inc., Cambridge, Massachusetts., Irwin S; H3 Biomedicine Inc., Cambridge, Massachusetts., Kim A; H3 Biomedicine Inc., Cambridge, Massachusetts., Montesion M; Foundation Medicine Inc., Cambridge, Massachuetts., Moriarty AD; START, Preclinical Research, San Antonio, Texas., Murugesan K; Foundation Medicine Inc., Cambridge, Massachuetts., Nguyen TV; H3 Biomedicine Inc., Cambridge, Massachusetts., Rimkunas V; H3 Biomedicine Inc., Cambridge, Massachusetts., Sahmoud T; H3 Biomedicine Inc., Cambridge, Massachusetts., Wick MJ; START, Preclinical Research, San Antonio, Texas., Yao S; H3 Biomedicine Inc., Cambridge, Massachusetts., Zhang X; H3 Biomedicine Inc., Cambridge, Massachusetts., Zeng H; H3 Biomedicine Inc., Cambridge, Massachusetts., Vaillancourt FH; H3 Biomedicine Inc., Cambridge, Massachusetts., Bolduc DM; H3 Biomedicine Inc., Cambridge, Massachusetts., Larsen N; H3 Biomedicine Inc., Cambridge, Massachusetts., Zheng GZ; H3 Biomedicine Inc., Cambridge, Massachusetts., Prajapati S; H3 Biomedicine Inc., Cambridge, Massachusetts., Zhu P; H3 Biomedicine Inc., Cambridge, Massachusetts., Korpal M; H3 Biomedicine Inc., Cambridge, Massachusetts.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2022 Jun 01; Vol. 21 (6), pp. 890-902.